A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.
By inhibiting a certain protein, the researchers were able to reduce the signals that trigger an inflammation. The study is published in Science and was done in collaboration with the University of Texas Medical Branch, Uppsala University and Stockholm University.
“We’ve developed a new drug molecule that inhibits inflammation,” says Professor Thomas Helleday, at the Department of Oncology-Pathology, Karolinska Institutet, Sweden, who co-led the study with Dr Torkild Visnes and Dr Armando Cázares-Körner. “It acts on a protein that we believe is a general mechanism for how inflammation arises in cells.”
The discovery is the result of many years of research by Thomas Helleday’s group on how DNA is repaired by the body. One of the objectives has been to fight cancer by targeting damage to the tumour cells’ DNA. Several breakthroughs have already been reported, which have led, amongst other things, to a new treatment for congenital breast and ovarian cancer using so-called PARP inhibitors, which has been available for some years.
Trials on mice
It was when developing a new molecule for inhibiting the enzyme that repairs oxygen damage to DNA that the researchers found, to their surprise, that it also dampened inflammation. It turned out that the enzyme OGG1, apart from repairing DNA, also triggers inflammation.
The inhibitor blocks the release of inflammatory proteins, such as TNF alpha. In trials on mice with acute pulmonary disease, the researchers succeeded in dampening the inflammation.
“This discovery could give rise to a new treatment for a very serious condition,” says Professor Helleday. “We’ll now be developing our OGG1 inhibitor and examining whether it can lead to new treatments for inflammatory diseases in order to cure or relieve diseases such as sepsis, COPD and severe asthma.”
The discovery was made in collaboration with Professor Istvan Boldogh from the University of Texas Medical Branch, USA.
The repair pathway on which OGG1 operates was discovered by Tomas Lindahl at Karolinska Institutet in the 1970s, an achievement that earned him the Nobel Prize in Chemistry in 2015.
Collaboration between several universities
The study was a collaboration between Karolinska Institutet, Uppsala University and Stockholm University in Sweden and the University of Texas Medical Branch, USA.
Learn more: New inflammation inhibitor discovered
The Latest on: Anti-inflammatory drug
[google_news title=”” keyword=”anti-inflammatory drug” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Anti-inflammatory drug
- Anticancer drugs could lead to new sepsis treatmenton January 12, 2023 at 1:31 pm
Portuguese researchers say because anti-cancer drugs limit inflammation, they could be a potential treatment for sepsis.
- Trail Running and Drug-Testing: Where Do We Go From Here?on January 11, 2023 at 12:03 am
For years, trail running has had a reputation as a clean sport with a bit of a "wild west" vibe. Because there is very little authentic drug testing in trail and ultra-distance running, no ...
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Market with Highly Lucrative Segment to Expand Significantly | Including 110 Pages Reporton January 10, 2023 at 9:49 pm
Market 2023 by Technology, Manufacturers, Regions, Type, and Application, Forecast Guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors ...
- Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditionson January 10, 2023 at 5:30 am
Collaboration with The William Harvey Research Institute and Queen Mary University of London- PL-8177 displayed pro-resolving and ...
- Too Many And Too Explicit: Most People Want Drug Ads Off The Airwayson January 10, 2023 at 5:25 am
A survey dives into objections that people cite to prolific drug advertising, including overall volume, repetitive airings, and the narrations of “heinous” side effects or ...
- Anti-inflammatory therapeutics market size to increase by USD 39.32 billion; North America to contribute 45% of market growth - Technavioon January 9, 2023 at 3:00 pm
The Anti-inflammatory Therapeutics Market by Application, Drug Class, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market size is forecast to grow by USD 39.
- Osteoarthritis: New Drug May Help Stop Symptomson January 5, 2023 at 7:28 pm
Researchers have learned that a drug called talarozole could help reduce the adverse effects caused by low levels of retinoic acid in the body — which is linked to the development and symptoms of OA.
- The Best Medications to Treat Back Painon January 5, 2023 at 12:55 pm
For example, ibuprofen (Advil) is a non-steroidal anti-inflammatory drug (NSAID) that’s effective for treating inflammatory back pain. It's often the first-line treatment recommended when you ...
- Abivax Publishes Novel Data with Respect to Obefazimod's Anti-Inflammatory Mechanism of Actionon January 4, 2023 at 11:44 pm
Abivax believes obefazimod is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124) with potent anti-inflammatory ...
via Bing News